🔗 Share this article

This year's prestigious award in Physiology or Medicine was granted for revolutionary findings that clarify how the body's defense network attacks dangerous pathogens while protecting the healthy tissues.

Three esteemed researchers—from Japan Prof. Sakaguchi and US experts Dr. Brunkow and Dr. Ramsdell—received this honor.

Their work identified unique "sentinels" within the defense system that remove malfunctioning defense cells capable of attacking the body.

The findings are now enabling innovative treatments for immune disorders and cancer.

These laureates will divide a prize fund worth 11m SEK.

Decisive Findings

"The research has been essential for understanding how the immune system functions and why we don't all suffer from serious self-attack conditions," commented the chair of the Nobel Committee.

The trio's research address a core question: In what way does the immune system defend us from countless invaders while leaving our healthy cells intact?

The immune system employs white blood cells that scan for indicators of infection, including pathogens and germs it has not met before.

Such cells utilize sensors—known as recognition units—that are generated by chance in a vast number of combinations.

This gives the defense network the ability to combat a broad range of threats, but the randomness of the process inevitably produces white blood cells that can attack the body.

Protectors of the Body

Researchers previously knew that some of these harmful defense cells were eliminated in the immune organ—where white blood cells mature.

The latest Nobel Prize recognizes the identification of regulatory T-cells—described as the body's "security guards"—which travel through the body to neutralize other immune cells that assault the healthy cells.

It is known that this mechanism malfunctions in autoimmune diseases such as juvenile diabetes, multiple sclerosis, and RA.

A Nobel panel added, "These discoveries have laid the foundation for a new field of investigation and spurred the creation of innovative therapies, for example for cancer and autoimmune diseases."

Regarding malignancies, regulatory T-cells prevent the system from fighting the growth, so studies are aimed at reducing their quantity.

For autoimmune diseases, trials are exploring boosting regulatory T-cells so the body is not being harmed. A comparable method could also be effective in reducing the risks of transplanted organ failure.

Innovative Studies

Prof Sakaguchi, from Osaka University, performed experiments on mice that had their immune gland removed, causing self-attack conditions.

He demonstrated that introducing immune cells from other animals could stop the disease—suggesting there was a system for preventing defenders from harming the host.

Dr. Brunkow, from the Institute for Systems Biology in a US city, and Dr. Ramsdell, currently at Sonoma Biotherapeutics in a California city, were investigating an genetic immune disorder in mice and humans that led to the discovery of a gene vital for the way regulatory T-cells operate.

"The groundbreaking work has revealed how the immune system is controlled by T-reg cells, preventing it from accidentally targeting the body's own tissues," said a prominent physiology expert.

"The research is a striking illustration of how basic biological research can have broad implications for public health."